Author: admin

“Glioblastoma Market”

(Albany, USA) DelveInsight’s “Glioblastoma Market Insights, Epidemiology and Market Forecast– 2034” report delivers an in-depth understanding of the Glioblastoma, historical and forecasted epidemiology as well as the Glioblastoma market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

The Glioblastoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Glioblastoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Glioblastoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Glioblastoma market.

Discover which therapies are expected to grab the Glioblastoma Market Share @ Glioblastoma Market Outlook

Key Takeaways from the Glioblastoma Market Report

• The increase in Glioblastoma Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Glioblastoma Market is anticipated to witness growth at a considerable CAGR.

• The leading Glioblastoma Companies working in the market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.

• Promising Glioblastoma Pipeline Therapies in the various stages of development include ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
• In May 2025, CNS Pharmaceuticals Inc. announced a study that is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria.
• In May 2025, In8bio Inc . Conducted a Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.
• In April 2025, Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that the FDA has approved an Investigational Device Exemption (IDE) application to initiate a pilot study for the treatment of patients with recurrent glioblastoma (GBM) using the Alpha DaRT technology.
• In December 2024, Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of glioblastoma (GBM) following its Type C clinical meeting with the United States Food and Drug Administration (FDA).
• On October 15, 2024, the FDA granted Fast Track designation to LP-184, a small-molecule alkylating agent developed by Lantern Pharma for the treatment of glioblastoma (GBM). LP-184 induces tumor cell death through DNA damage and is currently in a Phase 1a trial assessing its safety and tolerability in patients with various solid tumors, including GBM. The Fast Track status aims to accelerate the development and review of LP-184, particularly given the limited treatment options for aggressive brain cancers like GBM.
• April 2024:- Boston Scientific Corporation- FRONTIER: A Feasibility Study to Evaluate the Safety of the TheRaSphere GliOblastoma (GBM) Device iN PaTIEnts With Recurrent GBM. Glioblastoma (GBM) is a highly aggressive brain cancer with a grave prognosis, resulting in <7% of patients surviving to five years post-diagnosis. External beam radiotherapy (EBRT) is currently a mainstay treatment for GBM; however, the dose delivered is limited by side effects. The targeted radiotherapy of the TheraSphere GBM Y-90 Glass Microsphere System (TheraSphere GBM) has promising potential to provide GBM patients with reduced side effects compared to external beam radiotherapy as well as a more effective treatment for this catastrophic disease.
• April 2024:- TJ Biopharma Co., Ltd. – A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT). A Phase 2, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients with Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT).

Stay ahead in oncology R&D with our latest pipeline review glioblastoma treatment market overview, covering immunotherapies and targeted agents, visit @ Glioblastoma Treatment Market Landscape

Glioblastoma Overview

Glioblastoma (GBM) is an aggressive and the most common primary malignant brain tumor in adults. Classified as a grade IV astrocytoma by the World Health Organization, it originates from astrocytes, the supportive glial cells in the brain. GBM is characterized by rapid growth, extensive infiltration into surrounding brain tissue, and significant heterogeneity at the cellular and molecular levels.

Patients often present with neurological symptoms such as headaches, seizures, cognitive decline, or focal deficits, depending on the tumor’s location. Diagnosis typically involves magnetic resonance imaging (MRI) and confirmation via biopsy or surgical resection, which also serves as an initial treatment step.

Standard treatment includes maximal safe surgical resection, followed by concurrent radiotherapy and temozolomide chemotherapy. Despite aggressive multimodal therapy, GBM remains highly resistant to treatment, with a median survival of 15–18 months. Recurrence is almost inevitable, and treatment options for recurrent disease are limited.

Molecular profiling of GBM, including markers like MGMT promoter methylation and IDH mutation status, guides prognosis and treatment decisions. Emerging therapies, such as tumor-treating fields (TTFs), immunotherapy, and targeted molecular inhibitors, are under investigation. While these advances offer hope, GBM remains a formidable challenge, highlighting the urgent need for innovative therapies.

Glioblastoma Epidemiology Insights

The epidemiology section of Glioblastoma offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Glioblastoma Epidemiology trends @ Glioblastoma Epidemiological Insights

Glioblastoma Drugs Market

The Glioblastoma Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Glioblastoma signaling in Glioblastoma are likely to uncover new therapeutic targets and further expand treatment options for patients.

Glioblastoma Treatment Market Landscape

The Glioblastoma treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Glioblastoma has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

Glioblastoma Market Outlook

The report’s outlook on the Glioblastoma market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Glioblastoma therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Glioblastoma drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Glioblastoma market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

The glioblastoma market is driven by several critical factors, most notably the rising incidence of glioblastoma cases worldwide and the urgent need for effective treatments for this aggressive brain tumor. Advances in molecular diagnostics and personalized medicine have also bolstered market growth by enabling targeted therapies and precision treatment approaches. Increased research funding, a robust clinical pipeline featuring novel immunotherapies and targeted agents, and greater awareness among healthcare professionals further support market expansion. However, the market faces significant barriers, including the complex biology of glioblastoma, which leads to high recurrence rates and limited overall survival despite aggressive treatment. The blood-brain barrier remains a major obstacle, restricting the delivery of many systemic therapies to tumor sites. Additionally, the high costs of drug development, stringent regulatory hurdles, and limited success rates in clinical trials pose challenges to bringing new therapies to market. Together, these drivers and barriers shape a challenging yet evolving landscape for glioblastoma management.

Glioblastoma Drugs Uptake

The drug chapter of the Glioblastoma report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Glioblastoma.

A comprehensive pipeline review glioblastoma treatment market analysis reveals promising investigational drugs and upcoming clinical trial milestones.

Learn more about the FDA-approved drugs for Glioblastoma @ Drugs for Glioblastoma Treatment

Major Glioblastoma Companies

Several Glioblastoma Companies working in the market include Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.

Scope of the Glioblastoma Market Research Report

• Coverage- 7MM

• Glioblastoma Companies- Bayer, Chimerix, Aivita Biomedical, Denovo Biopharma, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, CNS Pharmaceuticals, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Genenta Science, Enterome, Inovio Pharmaceuticals, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, and TME Pharma, and others.

• Glioblastoma Pipeline Therapies- ITI-1000 (pp65 DC Vaccine), VBI-1901, Selinexor (KPT-330), Trans Sodium Crocetinate, Ofranergene obadenovec (VB-111), Temodar/Temodal, Avastin, Azeliragon, PLX3397, Temozolomide, VXM01, Avelumab, and others.
• Glioblastoma Market Dynamics: Glioblastoma Market Drivers and Barriers
• Glioblastoma Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Glioblastoma Drugs in development @ Glioblastoma Clinical Trials and FDA Approvals

Table of Content

1. Key Insights

2. Report Introduction

3. Glioblastoma Multiforme Market Overview at a Glance

4. Epidemiology and Market Forecast Methodology

5. Executive Summary of Glioblastoma Multiforme (GBM)

6. Key Events

7. Glioblastoma SWOT Analysis

8. Disease Background and Overview: Glioblastoma Multiforme

9. Glioblastoma Treatment

10. Guidelines and Recommendations from Different Organizations

11. Glioblastoma Epidemiology and Patient Population

12. Glioblastoma Patient Journey

13. Key Endpoints in Glioblastoma Multiforme

14. Glioblastoma Marketed Products

15. Emerging Glioblastoma Drugs

16. Glioblastoma Market: Seven Major Market Analysis

17. Glioblastoma KOL Views

18. Glioblastoma Unmet Needs

19. Glioblastoma Market Access and Reimbursement

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/competitive-intelligence-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Glioblastoma Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Treatment, Therapies and Companies by DelveInsight

“Frontotemporal Dementia Drugs Market”

(Albany, USA) DelveInsight’s Frontotemporal Dementia Market Insights report includes a comprehensive understanding of current treatment practices, frontotemporal dementia emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan].

The overall market for frontotemporal dementia is expected to grow with the anticipated launch of emerging therapies, including Latozinemab, PBFT02, TAK-594/DNL593, and others, increased awareness, and extensive research in the forecast period (2025–2034).

Request for sample report @ Frontotemporal Dementia Market Report

Key Takeaways from the Frontotemporal Dementia Market Report

• According to DelveInsight’s analysis, the market size for frontotemporal dementia was found to be USD 60 million in the US in 2024.
• According to DelveInsight’s analysis, the total diagnosed prevalent cases of FTD in 7MM were found to be ~130K in 2024 and are estimated to rise with a significant CAGR throughout the forecast period (2025–2034).
• The highest proportion of FTD cases were observed in the bvFTD in the 7MM, while the fewest cases were found in language variant FTD (primary progressive aphasia).
• Leading frontotemporal dementia companies developing emerging therapies, such as Alector, Passage Bio, Prevail Therapeutics, Denali Therapeutics, GSK, Vesper Bio, Takeda, and others, are developing new frontotemporal dementia treatment drugs that can be available in the frontotemporal dementia market in the coming years.
• The promising frontotemporal dementia therapies in the pipeline include Latozinemab, PBFT02, TAK-594/DNL593, PR006, VES001, and others.
• Latozinemab, the most advanced therapy for FTD-GRN, with Orphan Drug Designation (ODD), Breakthrough Therapy (BTD), and Fast Track Designations for FTD, holds a strong regulatory momentum.

Discover frontotemporal dementia new treatment @ New Treatments for Frontotemporal Dementia

Frontotemporal Dementia Overview

Frontotemporal dementia (FTD) is a neurocognitive disorder marked by progressive impairment in executive function, behavior, and language. Its clinical presentation is highly variable, encompassing behavioral shifts, emotional disturbances, communication challenges, and sometimes motor deficits. A significant risk factor is family history, with 15–40% of cases associated with genetic mutations, though the precise underlying cause often remains unidentified.

Diagnosis is difficult due to the broad and overlapping nature of symptoms with other neurological or psychiatric conditions, the absence of definitive biomarkers, and the reliance on thorough clinical evaluation. Misdiagnosis is frequent, as FTD can closely resemble psychiatric illnesses or other forms of dementia, making accurate detection challenging.

Frontotemporal Dementia Market Dynamics

The frontotemporal dementia market dynamics are expected to change in the coming years. Emerging drugs are poised for market leadership due to the absence of an approved treatment for FTD, as rising case numbers drive urgent demand, renewed research interest fuels hope for improved diagnostics and expanded treatment options, and novel therapeutic approaches offer ample opportunities for breakthroughs.

As potential therapies are being investigated for the treatment of frontotemporal dementia, it is safe to predict that the treatment space will significantly impact the frontotemporal dementia market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the frontotemporal dementia market in the 7MM.

However, several factors may impede the growth of the frontotemporal dementia market. The exact pathology of the disorder remains unknown, and its heterogeneous nature makes clinical trials challenging, with few reaching completion; coupled with the high rate of misdiagnosis or delayed diagnosis, often due to symptom overlap with other disorders, these factors collectively weaken the market and pose significant hurdles for targeted treatment and the success of upcoming drugs.

Moreover, frontotemporal dementia treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the frontotemporal dementia market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the frontotemporal dementia market growth.

To know more about FDA-approved drugs for frontotemporal dementia, visit @ Frontotemporal Dementia Treatment Drug Market

Frontotemporal Dementia Treatment Market

The frontotemporal dementia treatment drug market is segmented by drug classes, including selective serotonin reuptake inhibitors (SSRIs) such as citalopram and fluoxetine, antipsychotics, cholinesterase inhibitors like donepezil, rivastigmine, and galantamine, NMDA receptor antagonists such as memantine, and benzodiazepine-based anti-anxiety medications.

SSRIs and related drugs are considered promising for FTD patients, as they have shown success in managing psychiatric symptoms that are similar to behavioral issues seen in FTD, particularly in those with the behavioral variant (bvFTD). Antidepressants and antipsychotics are frequently prescribed SSRIs for managing these symptoms.

However, research indicates that cholinesterase inhibitors are generally ineffective in treating FTD and progressive supranuclear palsy (PSP) and may even worsen behavioral or motor symptoms. Donepezil, rivastigmine, and galantamine remain the most commonly administered cholinesterase inhibitors in FTD and similar conditions. Memantine, an NMDA receptor antagonist approved for Alzheimer’s disease, has been explored for its potential neuroprotective effects by targeting excitotoxicity linked to NMDA receptor overactivity.

Complementary therapies also play a vital role in FTD management. Physical therapy focusing on gait and balance can help reduce fall risk and improve survival. Speech therapy, particularly with specialists in neurodegenerative aphasias, benefits individuals with primary progressive aphasia. Additionally, occupational therapy assessments for home safety can enhance daily functioning for those with motor coordination difficulties or apraxia.

Growing research interest in FTD is paving the way for future breakthroughs and the development of innovative treatments targeting new molecular pathways.

Frontotemporal Dementia Pipeline Therapies and Key Companies

Currently, several emerging players are at the forefront, including Alector/GSK (latozinemab), Passage Bio (PBFT02), Prevail Therapeutics (PR006), Denali Therapeutics/Takeda (TAK-594/DNL593), and Vesper Bio (VES001), among others.

Alector’s lead candidate, latozinemab, is a monoclonal antibody designed to regulate progranulin, a key immune modulator in the brain linked to various neurodegenerative diseases. Now in Phase III trials for FTD-GRN, latozinemab has received Orphan Drug Designation, Breakthrough Therapy, and Fast Track status from the U.S. FDA. The global INFRONT-3 Phase III study is enrolling symptomatic and at-risk FTD-GRN individuals.

Passage Bio is advancing PBFT02, a gene therapy using an AAV1 vector to introduce a modified GRN gene into patient cells. This therapy is being evaluated in Phase I/II trials for FTD with GRN mutations, supported by an active IND and regulatory clearances across several countries. The company also plans to initiate dosing in its upliFT-D trial for FTD-C9orf72 in early 2025.

Denali Therapeutics, together with Takeda, is developing TAK-594 (DNL593), an intravenous progranulin replacement therapy built on Denali’s Protein Transport Vehicle (PTV) platform. This “brain shuttle” approach facilitates delivery across the blood–brain barrier, with early Phase I/II data showing dose-related increases in CSF progranulin levels. Dosing in FTD-GRN patients is underway.

Prevail Therapeutics is focused on PR006, a one-time AAV9 gene therapy that delivers a functional GRN gene to elevate progranulin in the brain. It holds Orphan Drug Designation in the U.S. and EU, along with Fast Track status from the FDA, and is being tested in the PROCLAIM Phase I/II trial.

These pipeline therapies are expected to significantly impact the FTD treatment landscape. As they advance through clinical stages and secure regulatory approvals, they promise to redefine care standards, drive innovation, and open new avenues for economic growth.

Discover more about frontotemporal dementia drugs in development @ Frontotemporal Dementia Clinical Trials

Recent Developments in the Frontotemporal Dementia Market

• In May 2025, Vesper Bio announced that it had reached an important enrolment milestone in the Phase Ib/IIa of its ongoing SORT-IN-2 study of VES001 for GRN-FTD.
• In May 2025, Passage Bio presented the process development data of a high productivity, suspension-based manufacturing process for PBFT02 at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting 2025.

Frontotemporal Dementia Epidemiology Segmentation

The frontotemporal dementia epidemiology section provides insights into the historical and current frontotemporal dementia patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.

The frontotemporal dementia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:

• Frontotemporal Dementia Diagnosed Prevalent Cases
• Type-specific Frontotemporal Dementia Diagnosed Prevalent Cases
• Gene-specific Frontotemporal Dementia Diagnosed Prevalent Cases

Scope of the Frontotemporal Dementia Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, the EU4 (Germany, France, Italy, and Spain) and The United Kingdom, and Japan].
• Frontotemporal Dementia Market Size in 2024 (US): USD 60 Million
• Key Frontotemporal Dementia Companies: Alector, Passage Bio, Prevail Therapeutics, Denali Therapeutics, GSK, Vesper Bio, Takeda, and others.
• Key Frontotemporal Dementia Therapies: Latozinemab, PBFT02, TAK-594/DNL593, PR006, VES001, and others
• Therapeutic Assessment: Frontotemporal Dementia current marketed and emerging therapies
• Frontotemporal Dementia Market Dynamics: Key Market Forecast Assumptions of Emerging Frontotemporal Dementia Drugs and Market Outlook
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL’s views, Analyst’s views, Frontotemporal Dementia Market Access and Reimbursement

Download the report to understand which factors are driving frontotemporal dementia market trends @ Frontotemporal Dementia Market Forecast

Table of Contents

1. Frontotemporal Dementia Market Key Insights

2. Frontotemporal Dementia Market Report Introduction

3. Frontotemporal Dementia Market Overview at a Glance

4. Frontotemporal Dementia Market Executive Summary

5. Disease Background and Overview

6. Frontotemporal Dementia Treatment and Management

7. Frontotemporal Dementia Epidemiology and Patient Population

8. Patient Journey

9. Frontotemporal Dementia Marketed Drugs

10. Frontotemporal Dementia Emerging Drugs

11. Seven Major Frontotemporal Dementia Market Analysis

12. Frontotemporal Dementia Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Unmet Needs

16. SWOT Analysis

17. Appendix

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Frontotemporal Dementia Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Target Population, Revenue, Statistics, MOA, ROA and Companies DelveInsight

“Attention Deficit Hyperactivity Disorder Clinical Trials”

(Albany, USA) DelveInsight’s “Attention Deficit Hyperactivity Disorder Pipeline Insight, 2025” comprehensively analyzes the current clinical landscape and growth prospects in the Attention Deficit Hyperactivity Disorder market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging Attention Deficit Hyperactivity Disorder drugs, the Attention Deficit Hyperactivity Disorder pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Download DelveInsight’s comprehensive report to uncover breakthrough therapies, clinical progress, and future market opportunities @ Attention Deficit Hyperactivity Disorder Pipeline Outlook

Key Takeaways from the Attention Deficit Hyperactivity Disorder Pipeline Report

• DelveInsight’s Attention Deficit Hyperactivity Disorder Pipeline analysis depicts a robust space with 20+ active players working to develop 22+ pipeline drugs for Attention Deficit Hyperactivity Disorder treatment.
• The leading Attention Deficit Hyperactivity Disorder companies include Cingulate Therapeutics, Otsuka Pharmaceutical, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, KemPharm, Arbor Pharmaceuticals, Ensysce Biosciences, 3Z Pharmaceuticals, Shire, Takeda, New River Pharmaceuticals, Aevi Genomic Medicine LLC, Sumitomo Pharma America Inc., Orient Pharma Co. Ltd., Durect, Rhodes Pharmaceuticals L.P., Purdue Pharma LP, CoMentis, Johnson & Johnson Ltd., Xian-Janssen Pharmaceutical Ltd., Shionogi Inc., Pfizer, Novartis, Neos Therapeutics Inc., Janssen Pharmaceuticals, and others are evaluating their lead assets to improve the Attention Deficit Hyperactivity Disorder treatment landscape.
• Key Attention Deficit Hyperactivity Disorder pipeline therapies in various stages of development include CTx-1301, Centanafadine, PDC-1421, and others.
• In January 2025, generic drugmaker Granules received final approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate Capsules, a medication for Attention Deficit Hyperactivity Disorder (ADHD), available in multiple strengths.
• In December 2024, Granules India received FDA approval for Lisdexamfetamine Dimesylate chewable tablets, its generic version of Takeda Pharmaceuticals’ Vyvanse. The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and moderate to severe binge eating disorder (BED).

Request a sample and discover the recent breakthroughs happening in the Attention Deficit Hyperactivity Disorder pipeline landscape @ Attention Deficit Hyperactivity Disorder Treatment Drugs

Attention Deficit Hyperactivity Disorder Overview

ADHD is a neurodevelopmental disorder that significantly impacts a child’s ability to function, characterized by persistent patterns of inattention, hyperactivity, and impulsivity. Previously classified as separate conditions-Attention Deficit Disorder and Attention Deficit Hyperactivity Disorder-the DSM-IV merged them into a single diagnosis with three subtypes: predominantly inattentive, predominantly hyperactive, and combined type.

Symptoms typically emerge in early childhood and include difficulty focusing, disorganization, forgetfulness, and trouble completing tasks. For a diagnosis, these symptoms must appear before age 12, persist for at least six months, and disrupt daily life across multiple settings, such as home and school. ADHD can affect social interactions, academic performance, and even increase the likelihood of risky behaviors and job instability.

As a disorder linked to executive dysfunction, ADHD primarily affects the frontal lobe, impairing attention, decision-making, and emotional regulation. Children with ADHD may struggle with frustration, impulsivity, and social interactions, often being misperceived as troublemakers. Brain abnormalities, including reduced size in the anterior cingulate gyrus and dorsolateral prefrontal cortex (DLPFC), contribute to deficits in goal-directed behavior, with decreased activity in the frontostriatal region observed through fMRI scans.

The exact cause of ADHD remains unclear but involves both genetic and environmental influences. It is one of the most heritable psychiatric disorders, with higher concordance in identical twins and an increased risk among siblings. Environmental factors such as prenatal exposure to smoking, alcohol, nutritional deficiencies, and viral infections have also been linked to its development. Research suggests that lower dopamine receptor availability in the frontal lobes and noradrenergic system involvement may play a role in the disorder’s pathology.

Find out more about Attention Deficit Hyperactivity Disorder medication @ ADHD Medication and Companies

Attention Deficit Hyperactivity Disorder Treatment Analysis: Drug Profile

CTx-1301: Cingulate Therapeutics

CTx-1301 leverages Cingulate’s Precision Timed Release (PTR) technology to develop an advanced multi-core dexmethylphenidate formulation for ADHD treatment. This innovative tablet integrates immediate and sustained release layers, ensuring precise drug delivery throughout the day. Designed for rapid onset, full-day efficacy, and a controlled decline in plasma levels, CTx-1301 aims to optimize symptom management. Currently, the drug is in Phase III clinical trials for ADHD.

Centanafadine: Otsuka Pharmaceutical

Centanafadine, a triple-reuptake inhibitor targeting serotonin, norepinephrine, and dopamine, was initially developed by Neurovance before Otsuka Pharmaceutical acquired its rights in 2017. Two Phase III trials, involving approximately 900 adults (ages 18-55) with ADHD, assessed its efficacy through randomized, double-blind, placebo-controlled studies. Participants received either 100 mg or 200 mg doses twice daily, or a placebo. Centanafadine demonstrated significant symptom improvements compared to placebo across primary and key secondary endpoints. Safety data from both studies indicated no adverse events affecting more than 7% of participants.

Key Attention Deficit Hyperactivity Disorder Therapies and Companies

• CTx-1301: Cingulate Therapeutics
• Centanafadine: Otsuka Pharmaceutical
• PDC-1421: BioLite, Inc.

Learn more about the novel and emerging Attention Deficit Hyperactivity Disorder pipeline therapies @ Attention Deficit Hyperactivity Disorder Clinical Trials

Attention Deficit Hyperactivity Disorder Therapeutics Assessment

By Product Type

• Mono
• Combination
• Mono/Combination.

By Stage

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Attention Deficit Hyperactivity Disorder Pipeline Report

• Coverage: Global
• Key Attention Deficit Hyperactivity Disorder Companies: Cingulate Therapeutics, Otsuka Pharmaceutical, BioLite, Mind Medicine, Tris Pharma, RespireRx Pharmaceuticals, KemPharm, Arbor Pharmaceuticals, Ensysce Biosciences, 3Z Pharmaceuticals, Shire, Takeda, New River Pharmaceuticals, Aevi Genomic Medicine LLC, Sumitomo Pharma America Inc., Orient Pharma Co. Ltd., Durect, Rhodes Pharmaceuticals L.P., Purdue Pharma LP, CoMentis, Johnson & Johnson Ltd., Xian-Janssen Pharmaceutical Ltd., Shionogi Inc., Pfizer, Novartis, Neos Therapeutics Inc., Janssen Pharmaceuticals, and others.
• Key Attention Deficit Hyperactivity Disorder Pipeline Therapies: CTx-1301, Centanafadine, PDC-1421, and others.

Dive deep into rich insights for drugs used for Attention Deficit Hyperactivity Disorder treatment; visit @ Attention Deficit Hyperactivity Disorder FDA Approvals and Recent Development

Table of Contents

1. Introduction

2. Executive Summary

3. Attention Deficit Hyperactivity Disorder Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Attention Deficit Hyperactivity Disorder Pipeline Therapeutics

6. Attention Deficit Hyperactivity Disorder Pipeline: Late-Stage Products (Phase III)

7. Attention Deficit Hyperactivity Disorder Pipeline: Late-Stage Products (Phase III)

8. Attention Deficit Hyperactivity Disorder Pipeline: Mid-Stage Products (Phase II)

9. Attention Deficit Hyperactivity Disorder Pipeline: Early Stage Products (Phase I)

10. Therapeutic Assessment

11. Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Key Companies

14. Key Products

15. Unmet Needs

16. Market Drivers and Barriers

17. Future Perspectives and Conclusion

18. Analyst Views

19. Appendix

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Attention Deficit Hyperactivity Disorder Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, ROA, and Companies by DelveInsight